CoChat

Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression

Open access

Published version of a preprint

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Abstract Purpose: VEGF-targeted therapies have modest efficacy in cancer patients, but acquired resistance is common. The mechanisms underlying such resistance are poorly understood. Experimental Design: To evaluate the potential role of immune cells in the development of resistance to VEGF blockade, we first established a preclinical model of adaptive resistance to anti-VEGF therapy. Additional in vitro and in vivo studies were carried out to characterize the role of macrophages in such resistance. Results: Using murine cancer models of adaptive resistance to anti-VEGF antibody (AVA), we found a previously unrecognized role of macrophages in such resistance. Macrophages were actively recruited to the tumor microenvironment and were responsible for the emergence of AVA resistance. Depletion of macrophages following emergence of resistance halted tumor growth and prolonged survival of tumor-bearing mice. In a macrophage-deficient mouse model, resistance to AVA failed to develop, but could be induced by injection of macrophages. Downregulation of macrophage VEGFR-1 and VEGFR-3 expression accompanied upregulation of alternative angiogenic pathways, facilitating escape from anti-VEGF therapy. Conclusions: These findings provide a new understanding of the mechanisms underlying the modest efficacy of current antiangiogenesis therapies and identify new opportunities for combination approaches for ovarian and other cancers. Clin Cancer Res; 23(22); 7034–46. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-0647

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 97

Metadata

Authors
Dalton, H. J., Pradeep, S., McGuire, M., Hailemichael, Y., MA, S., Lyons, Y., Armaiz-Pena, G. N., Previs, R. A., Hansen, J. M., Rupaimoole, R., Gonzalez-Villasana, V., Cho, M. S., Wu, S. Y., Mangala, L. S., Jennings, N. B., Hu, W., Langley, R., Mu, H., Andreeff, M., Bar-Eli, M., Overwijk, W., Ram, P., Lopez-Berestein, G., Coleman, R. L., & Sood, A. K.
Affiliations
  • 1Departments of Gynecologic Oncology and Reproductive Medicine,
  • Medical College of Wisconsin (US)
  • 3Department of Melanoma Medical Oncology,
  • 4Experimental Therapeutics,
  • The University of Texas MD Anderson Cancer Center (US)
  • 8Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Corresponding author
Sood, Anil K.
Venue
Clinical Cancer Research
Published
2017-11-14
Volume
23
Issue
22
Pages
7034-7046
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2751214182
Cited by
97
References
31
Citations by year
2026: 3 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 15 · 2021: 14 · 2020: 12 · 2019: 10 · 2018: 9
FWCI
3.46
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • El Repositorio Academico Digital de la UANL (Universidad Autónoma de Nuevo León) (acceptedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (UH3TR000943)
  • National Cancer Institute (R35CA209904, P50CA098258, U01CA213759, R01CA109298, P50CA083639, P30CA016672, T32CA101642)
  • National Center for Advancing Translational Sciences
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
macrophages, anti-VEGF therapy resistance, VEGFR1, VEGFR-3, adaptive resistance, anti-angiogenic therapy, tumor microenvironment, macrophage recruitment, ovarian cancer, combination therapy
MeSH terms
Animals, Antineoplastic Agents, Cell Survival, Disease Models, Animal, Female, Humans, Macrophages, Neoplasms, Neovascularization, Pathologic, Promoter Regions, Genetic, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Receptors, Vascular Endothelial Growth Factor, Cell Line, Tumor, Cell Proliferation, Mice, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-0647
The paper
Dalton, H. J., Pradeep, S., McGuire, M., Hailemichael, Y., MA, S., Lyons, Y., Armaiz-Pena, G. N., Previs, R. A., Hansen, J. M., Rupaimoole, R., Gonzalez-Villasana, V., Cho, M. S., Wu, S. Y., Mangala, L. S., Jennings, N. B., Hu, W., Langley, R., Mu, H., Andreeff, M., . . . Sood, A. K. (2017). Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-0647

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.